Posts

Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership

on

FDA panel strongly backs Moderna's mRNA flu vaccine for older adults, with final decision expected by early August 2026.

on

Moderna adds commercial chief, expands Stephen Hoge's role

on

Moderna Agrees to Pay Up to $2.25 Billion to Settle COVID-19 Vaccine Patent Dispute with Arbutus and Roivant Subsidiary Genevant

on

CHMP Recommends Moderna's mCombriax Flu-COVID Vaccine for Adults 50+

on

FDA Reverses Course on Moderna's mRNA Flu Vaccine Application After Initial Rejection

on

FDA Reverses Course and Agrees to Review Moderna's mRNA Flu Vaccine

on

Moderna's Outright Flu Refusal Just the Latest Case of Crossed FDA Signals

on

Moderna Accuses FDA of Inconsistent Standards After Refusal to Review mRNA Flu Vaccine Application

on

Moderna and Merck Report Sustained 49% Risk Reduction in Recurrence or Death with mRNA-Keytruda Combo at Five Years in Melanoma Trial

on

Moderna Lands CEPI as New Backer for Its Pandemic Flu (H5 Bird Flu) Program

on

FDA Broadens COVID-19 Vaccine Safety Probe to Adults Under New Health Leadership

on

Moderna Halts Development of CMV Vaccine After Phase 3 Failure

on

Moderna Unveils Promising mRNA-4359 Cancer Antigen Therapy Data in Melanoma Ahead of ESMO 2025

on

Recent Moves in Biotech Leadership

on

FDA Approves Updated COVID-19 Shots from Pfizer, Moderna, Novavax with New Restrictions

on

HHS ousts MAHA implementation lead amid rushed cancellations of $500M in mRNA vaccine contracts

on

HHS Cancels $500 Million in BARDA-Funded mRNA Vaccine Contracts Amid Strategic Shift

on

Moderna Wins UK Appeals Court in Covid-19 Patent Case Against Pfizer/BioNTech

on

Moderna to Cut 10% of Workforce in $1.5B Cost-Saving Push

on